Clive Richard Thornley

Eisai Ltd. (United Kingdom) is a pharmaceutical company based in Hatfield, UK. Part of Eisai Co., Ltd., Eisai Ltd. prioritizes patients and their families by continually improving the benefits that healthcare can provide. The British company was founded in 1988 and Gary Bryan Hendler has been the CEO of the company since 2008.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of Eisai Co., Ltd., Eisai SAS is a French pharmaceutical company founded in 1996. The company is based in Courbevoie, France and strives to improve the lives of those who could benefit from their medicines. Eisai focuses its research on oncology and neurology, two areas presenting challenges in terms of public health. The company is committed to the fight against serious diseases, alongside patients, healthcare professionals, and public authorities.

Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Part of Eisai Co., Ltd., Sunplanet Co., Ltd. is a Japanese company that provides facility management, pharmaceutical analysis, and research development services. The company is based in Tokyo, Japan and was founded in 2001.

Asian Honda Motor Co. Ltd. distributes and exports motorcycles, automobiles, power products and components. The company was founded in October 1964 and is headquartered in Bangkok, Thailand.

Pacific Consultants Co., Ltd. provides integrated construction consulting services in engineering and infrastructure design. Its services include the land conservation, transport infrastructure, facility engineering, public management, information systems, project planning, energy and environment, geotechnical, business development, research and development; and others. The company was founded on September 4, 1951 and is headquartered in Tokyo, Japan.

Part of Eisai Co., Ltd., EA Pharma Co., Ltd. is a specialty pharmaceutical company based in Tokyo, Japan. The Japanese company specializes in digestive diseases such as inflammatory intestinal diseases and focuses on advanced research and development and marketing activities to solve unmet medical needs. EA Pharma Co. provides drug discovery research, development research related to gastrointestinal diseases, and drug discovery base technology research to meet the further medical needs of patients. The company's production department aims to create products that have effective and safety as a drug and ensure the quality of the product. EA Pharma Co. aims to be the largest digestive pharmacy in Japan, which was born in the integration of the digestive business of the Eisai group and the Ajinomoto group's digestive business.

Eisai Farmacéutica SA is a pharmaceutical company based in Madrid, Spain. Eisai Farmacéutica SA operates as a Spanish pharmaceutical company. Part of Eisai Co., Ltd., the company was founded in 2001. The CEO is Gary Bryan Hendler.

Part of Eisai Co., Ltd., Eisai GmbH is a German pharmaceutical company that specializes in research and development of innovative treatments for neurological and oncological diseases. The company is based in Frankfurt, Germany. The CEOs of the company are Gary Bryan Hendler, Nicholas Conrad Burgin.

Part of Eisai Co., Ltd., Eisai R&D Management Co., Ltd. engages in research and development of pharmaceuticals. The company is based in Bunkyo, Japan.

Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa.

Japanese Chamber of Commerce Industry of New York, Inc. is non-profit organization that engages in facilitation of trade between the U.S. and Japan. The company was founded on November 14, 1932 by 14 prominent Japanese businessman, and is headquartered in New York, NY.

Part of Eisai Co., Ltd., Eisai Europe Ltd. is a British pharmaceutical company that manufactures and distributes pharmaceutical products. The company is based in Hatfield, UK and was founded in 2004.

Miura & Partners is a law office that provides the best results to clients. The private company is based in Tokyo, Japan. The Japanese company has a team of experienced lawyers and staff who utilize their knowledge and know-how to serve their clients effectively.

Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018.

Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The company's official corporate website provides information on their initiatives and HHC concept.